Abstract 3753
Background
The advanced practice nurse (APN), with ability to apply evidence in an integrated framework, assumes new roles and acts as benchmark for patient and other professionals. In the last two decades, nurses have developed new advanced roles. There is international experience of the implementation for new model, and organizational ways by integrating and integrate interventions for EPA. High positive results in coordinating services and multidisciplinary teams, facilitate continuity of care resulting better quality of life and greater satisfaction for patients.
Methods
Descriptive study with patients treated in the functional unit of the Catalan Institute of Oncology in year 2018. After literature review on roles for nurses in lung cancer, we review number of interventions and activity carried out by EPA.
Results
A total of 589 first cases lung cancer started their first treatment. Nurse visited 93.2% of them in the Lung Functional Unit (LFU). Type of treatment; surgical 26.41%, palliative chemotherapy 11.83%, concomitant chemo+ radiotherapy in 11.65%, immunotherapy 4.19%, TKis 3.1%, sequential chemo+radiotherapy 3.2%, neoadjuvant chemo 1.58%, chemo+immunotherapy 0.27%, neoadjuvant chemo+radiotherapy+surgery in 0.15% and the rest 37.62% with supportive or palliative treatment. A total of 2563 visits by nurse, 21.42% were first visits, 73.23% patients with active treatment and 4.7% that have completed the treatment but with some toxicity. A total of 3935 phone calls were attended by nurses, of which 81.19% were patients who made calls and 18.80% were nurses on phone for control. Derivation was resulting to emergency for 5.13% of patients. 87.79% cases presented in Lung tumors board needed coordination for visits and for complementary proves.
Conclusions
Incorporate the EPA in the multidisciplinary care helps to minimize complications, to improve coordination and avoid deviations of the care process. Key activities were: health education to patient and family on care and self-care, improve the compression of the disease, the treatment and the process, strengthen information, minimize problems and improve resources for the care process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1868 - Evaluation and diagnostic potential of plasma biomarkers in bladder cancer
Presenter: Veronika Voronova
Session: Poster Display session 3
Resources:
Abstract
3655 - Liquid biopsy assays using combined circulating tumor cells and circulating tumor DNA in the same patients for the diagnosis of primary lung cancer
Presenter: Yongjoon Suh
Session: Poster Display session 3
Resources:
Abstract
3685 - Peripheral Cytotoxic T Cell Correlates with Tumor Mutational Burden and is Predictive for Progression Free Survival in Advanced Breast Cancer
Presenter: Xiao-ran Liu
Session: Poster Display session 3
Resources:
Abstract
1050 - Splenic Metabolic Activity as Biomarker in Cervical Cancer
Presenter: Emiel De Jaeghere
Session: Poster Display session 3
Resources:
Abstract
1413 - Identification of distinct subtypes revealing prognostic and therapeutic relevance in diffuse type gastric cancer
Presenter: Seon-Kyu Kim
Session: Poster Display session 3
Resources:
Abstract
2140 - Recurrence risk evaluation in stage IB/IIA gastric cancer with TP53 codon 72 polymorphisms
Presenter: Satoshi Nishizuka
Session: Poster Display session 3
Resources:
Abstract
1573 - Identification and validation of a prognostic 4 genes signature for hepatocellular carcinoma: integrated ceRNA network analysis
Presenter: Yongcong Yan
Session: Poster Display session 3
Resources:
Abstract
1196 - Plasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805)
Presenter: Wenxin Xu
Session: Poster Display session 3
Resources:
Abstract
2657 - Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
Presenter: Katharina Nekolla
Session: Poster Display session 3
Resources:
Abstract
4900 - Molecular profiling and prognostic significance of TP53 mutations in Diffuse Large B Cell Lymphoma: identifying a high-risk subgroup
Presenter: Yuan-Kai Shi
Session: Poster Display session 3
Resources:
Abstract